News Feed Opinion Career Insight Dialogues Blog
Positive Societies Drugs Stories History
December, 2023
December 2023
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
The first randomised trial of a targeted agent versus immunotherapy plus chemotherapy in a biomarker-selected patient population – CUHK Medicine
Photo of Herbert Loong from CU Medicine
Oct 27, 2023, 04:23

The first randomised trial of a targeted agent versus immunotherapy plus chemotherapy in a biomarker-selected patient population – CUHK Medicine

” More than doubled lung cancer patients’ progression-free survival

Lung cancer is the leading cause of cancer-related deaths worldwide. It is also the cancer causing most deaths in Hong Kong, with about 4,000 cases every year. Non-small-cell lung cancer (NSCLC) accounts for over 80% of all lung cancers.

CU Medicine joined an international study to investigate the effect of targeted therapy on newly diagnosed advanced or metastatic NSCLC patients. For NSCLC patients with rearranged during transfection (RET) fusion-positive, one of the lung cancer oncogenic drivers, the medicine demonstrated a significantly improved progression-free survival. Their mean progression-free survival more than doubled that of those received current first-line standard treatment.

This study represents the first randomised trial of a targeted agent versus immunotherapy plus chemotherapy in a biomarker-selected patient population. The study results showed that targeted therapy can be the first-line standard of care in untreated RET fusion-positive advanced NSCLC patients. Dr Herbert Loong, a member of the international research team and Associate Professor from the Department of Clinical Oncology at CU Medicine presented the results of this multi-national clinical trial at the ESMO – European Society for Medical Oncology Congress on 21 October 2023. Details of study have just been published in the leading international journal The New England Journal of Medicine.”

For details click here.
Full article of study here.
Source:

clinical trial CUHK Medicine ESMO23 Herbert Loong immunotherapy NSCLC OncoDaily Oncology targeted therapy The New England Journal of Medicine.
Insight
Dec 9, 2023, 04:44
President Biden: It's good for the millions of Americans who can't afford their medications
Blog
Dec 9, 2023, 00:38
Thomas Hofmarcher: This is what a great panel discussion looks like!
Blog
Dec 9, 2023, 00:32
Zhiheng Xu: It's not just about how much statistics you know
Blog
Dec 9, 2023, 00:23
Priscilla Chan: Mark and I wrote our annual letter this year about how some of our earliest bets in science are letting us take advantage of this moment in AI
Blog
Dec 9, 2023, 00:18
David Fajgenbaum: 1 in 10 of us will develop a disease with no treatments
Career
Dec 8, 2023, 17:54
Dana-Farber News congratulates Sara Tolaney on receiving the Susan G. Komen 2023 Rising Star Researcher Award
Drugs
Dec 8, 2023, 17:50
Pure Biologics to test molecule PBA-0405 in project PB004 in a Phase 0 clinical trial in patients with solid tumors - The Antibody Society
Drugs
Dec 8, 2023, 17:46
Earle Burgess: Interested in new treatments being developed for advanced (urothelial) bladder cancer?
Insight
Dec 8, 2023, 17:40
Ibrahim Halil Sahin: A common question I received after my tweet on the PEGASUS trial...
Career
Dec 8, 2023, 17:35
Timothy M. Pawlik: Excited to announce Samilia Obeng-Gyasi as THE inaugural Endowed Surgical Professor in Health Equity
Insight
Dec 8, 2023, 17:32
Daniel Stover: Tumor genomic testing (TGT) is standard for MBC patients
Blog
Dec 8, 2023, 17:27
Tedros Adhanom Ghebreyesus: Gaza cannot afford to lose any more hospitals…
Insight
Positive
Societies
Career